MedPath

Topotecan

Generic Name
Topotecan
Brand Names
Hycamtin, Potactasol, Topotecan Hospira
Drug Type
Small Molecule
Chemical Formula
C23H23N3O5
CAS Number
123948-87-8
Unique Ingredient Identifier
7M7YKX2N15
Background

An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.

Indication

用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。

Associated Conditions
Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)
Clinical Trials
Related News

Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma

Phase 1
Completed
Conditions
Esophageal Cancer
Lung Cancer
Lymphoma
Interventions
Radiation: low-LET electron therapy
Radiation: low-LET photon therapy
First Posted Date
2004-06-10
Last Posted Date
2013-02-11
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
5
Registration Number
NCT00002625
Locations
🇺🇸

University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States

Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2
Withdrawn
Conditions
Lung Cancer
First Posted Date
2004-06-09
Last Posted Date
2014-01-15
Lead Sponsor
Case Comprehensive Cancer Center
Registration Number
NCT00006374

Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian Cancer

Phase 2
Conditions
Ovarian Cancer
First Posted Date
2004-06-09
Last Posted Date
2013-09-20
Lead Sponsor
SmithKline Beecham
Target Recruit Count
40
Registration Number
NCT00003733
Locations
🇬🇧

Mount Vernon Hospital, Northwood, England, United Kingdom

🇬🇧

Charing Cross Hospital, London, England, United Kingdom

Topotecan in Treating Patients With Recurrent Brain Tumors

Phase 2
Completed
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2004-06-09
Last Posted Date
2020-04-08
Lead Sponsor
NCIC Clinical Trials Group
Target Recruit Count
17
Registration Number
NCT00003372
Locations
🇨🇦

Kingston Regional Cancer Centre, Kingston, Ontario, Canada

🇨🇦

Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada

🇨🇦

CancerCare Manitoba, Winnipeg, Manitoba, Canada

and more 8 locations

Topotecan and Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Advanced Solid Tumors

Phase 1
Completed
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
First Posted Date
2004-06-04
Last Posted Date
2014-01-06
Lead Sponsor
Jonsson Comprehensive Cancer Center
Registration Number
NCT00004979

Topotecan, Paclitaxel, and Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer

Phase 2
Completed
Conditions
Lung Cancer
Interventions
Biological: filgrastim
First Posted Date
2004-06-03
Last Posted Date
2016-07-13
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
38
Registration Number
NCT00004055
Locations
🇺🇸

CCOP - Sioux Community Cancer Consortium, Sioux Falls, South Dakota, United States

🇺🇸

CCOP - Duluth, Duluth, Minnesota, United States

🇺🇸

CentraCare Clinic, Saint Cloud, Minnesota, United States

and more 16 locations

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2
Completed
Conditions
Fallopian Tube Cancer
Ovarian Cancer
Peritoneal Cavity Cancer
First Posted Date
2004-05-25
Last Posted Date
2013-04-17
Lead Sponsor
Fox Chase Cancer Center
Target Recruit Count
3
Registration Number
NCT00003944
Locations
🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian Cancer

Phase 1
Completed
Conditions
Ovarian Cancer
Primary Peritoneal Cavity Cancer
Interventions
Biological: recombinant interferon alfa
Drug: chemotherapy
Radiation: lutetium Lu 177 monoclonal antibody CC49
Radiation: yttrium Y 90 monoclonal antibody CC49
First Posted Date
2004-05-24
Last Posted Date
2013-02-05
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
30
Registration Number
NCT00002734
Locations
🇺🇸

University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States

Carboplatin Plus Topotecan in Treating Patients With Relapsed Acute Myelogenous Leukemia

Phase 2
Completed
Conditions
Leukemia
Interventions
First Posted Date
2004-05-20
Last Posted Date
2016-07-12
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
38
Registration Number
NCT00003255

Paclitaxel Plus Topotecan in Treating Patients With Solid Tumors

Phase 1
Completed
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
First Posted Date
2004-05-11
Last Posted Date
2013-06-03
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
20
Registration Number
NCT00002587
Locations
🇺🇸

NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy